Multifunctional Nanohybrid Based on Porous Silicon Nanoparticles, Gold Nanoparticles, and Acetalated Dextran for Liver Regeneration and Acute Liver Failure Theranostics

Liu, Zehua; Li, Yunzhan; Li, Wei; Xiao, Chen; Liu, Dongfei; Dong, Chao; Zhang, Ming; Mäkilä, Ermei; Kemell, Marianna; Salonen, Jarno; Hirvonen, Jouni; Zhang, Hongbo; Zhou, Dawang; Deng, Xianming; Santos, Hélder A.

doi:10.1002/adma.201703393

Cited by 90 publications

(76 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Microfluidic Production Of Nanoparticlesmentioning

confidence: 99%

“…In addition to form single core/shell structures, achieving a multihierarchical, multifunctional nanosystem, simultaneous coencapsulation of two or more types of NPs with altered physiochemical properties within one matrix, is also in great demand. Liu et al demonstrated the simultaneous coencapsulation of PSi NPs (≈200 nm) and gold (Au) nanoparticles (<5 nm) into a single polymeric matrix, and further applied it for acute liver failure theranostic therapy (Figure e) . The application of PSi NPs enhanced the loading degree of a hydrophobic drug (2,4‐((5,10‐dimethyl‐6‐oxo‐6,10‐dihydro‐5H‐pyrimido[5,4‐ b ] thieno[3,2‐e][1,4]diazepin‐2‐yl)amino)benzenesulfonamide) from 0.04% to 7.8%, and coresidence of Au NPs endowed the system with the capability to function as a contrasting agent for computed tomography (CT) imaging.…”

Section: Microfluidic Production Of Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Microfluidics for Production of Particles: Mechanism, Methodology, and Applications

Liu

Fontana

Python

et al. 2019

Small

Self Cite

View full text Add to dashboard Cite

In the past two decades, microfluidics‐based particle production is widely applied for multiple biological usages. Compared to conventional bulk methods, microfluidic‐assisted particle production shows significant advantages, such as narrower particle size distribution, higher reproducibility, improved encapsulation efficiency, and enhanced scaling‐up potency. Herein, an overview of the recent progress of the microfluidics technology for nano‐, microparticles or droplet fabrication, and their biological applications is provided. For both nano‐, microparticles/droplets, the previously established mechanisms behind particle production via microfluidics and some typical examples during the past five years are discussed. The emerging interdisciplinary technologies based on microfluidics that have produced microparticles or droplets for cellular analysis and artificial cells fabrication are summarized. The potential drawbacks and future perspectives are also briefly discussed.

show abstract

Section: Microfluidic Production Of Nanoparticlesmentioning

confidence: 99%

Section: Microfluidic Production Of Nanoparticlesmentioning

confidence: 99%

Microfluidics for Production of Particles: Mechanism, Methodology, and Applications

Liu

Fontana

Python

et al. 2019

Small

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the contrary, unlike the dissipation function of hydrophobic association in hydrogel, strong and stable hydrophobic association was proposed in the present study to restrict the hydrophilic swollen network, so to endow the hydrogels with high strength and elastic behavior. In this regard, the hydrophilic nature of dextran make it available in hydrogels construction, exhibiting remarkable biological and physi‐chemical properties . Poly (ε‐caprolactone) (PCL), possesses biocompatibility, was used biomaterials in several studies for its well performed mechanical properties .…”

Section: Discussionmentioning

confidence: 99%

Dextran‐based hydrogel with enhanced mechanical performance via covalent and non‐covalent cross‐linking units carrying adipose‐derived stem cells toward vascularized bone tissue engineering

Cai

Quan

et al. 2019

J Biomedical Materials Res

View full text Add to dashboard Cite

Hydrogels for biomedical applications were limited toward bone tissue engineering due to the poor mechanical performance. Tough hydrogels with strong and elastic features have received extensive attention, the application of which, however, was limited by their degradation. The present study introduced an approach to enhance mechanical properties of hydrogel while ensuring its degradation. Carboxyl dextran (Dex) was grafting modified by poly (ε‐caprolactone) (PCL), sequentially followed by being cross‐linked through polyethyleneglycol 400 (PEG400) to yield a gel with covalent cross‐linking units in DMSO. The gel was underwent solvent displacement in H2O to induce hydrophobic association of PCL to form non‐covalent cross‐linking units. The tough Dex‐g‐PCL hydrogel showed maximum strain of Dex‐g‐PCL hydrogel was 90% ± 6%, with the corresponding stress of 2.7 ± 0.2 MPa, which was significantly enhanced when comparing to dextran hydrogel (maximum strain 65% ± 5%, with the corresponding stress of 0.225 ± 0.06 MPa). Most hydrogel degraded after 12 w in vivo with only a little residues. Adipose‐derived stem cells (ASCs) proliferated well after being seeded in hydrogel to form micro‐mass at 14 days post‐seeding. In vitro and in vivo angiogenesis, as well as in vitro osteogenesis illustrated the potential of the Dex‐g‐PCL hydrogel carrying ASCs toward vascularized bone tissue engineering. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 1120–1131, 2019.

show abstract

“…XMU‐MP‐1 was dissolved in DMSO and injected intraperitoneally at a dose of 1 mg·kg −1 BW, given every 2 days. The dosing regimen was based on the pharmacokinetics data of XMU‐MP‐1 in a rodent model (Fan et al, ) and functional assays showing the effects of XMU‐MP‐1 injection (1 mg·kg −1 ) in reducing MOB1 phosphorylation in mice (Fan et al, ; Liu et al, ). XMU‐MP‐1 treatment started at 21 days post‐surgery for further 10 days.…”

Section: Methodsmentioning

confidence: 99%

Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU‐MP‐1, protects the heart against adverse effects during pressure overload

Triastuti

Nugroho

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

Background and PurposeThe Hippo pathway has emerged as a potential therapeutic target to control pathological cardiac remodelling. The core components of the Hippo pathway, mammalian Ste‐20 like kinase 1 (Mst1) and mammalian Ste‐20 like kinase 2 (Mst2), modulate cardiac hypertrophy, apoptosis, and fibrosis. Here, we study the effects of pharmacological inhibition of Mst1/2 using a novel inhibitor XMU‐MP‐1 in controlling the adverse effects of pressure overload‐induced hypertrophy.Experimental ApproachWe used cultured neonatal rat cardiomyocytes (NRCM) and C57Bl/6 mice with transverse aortic constriction (TAC) as in vitro and in vivo models, respectively, to test the effects of XMU‐MP‐1 treatment. We used luciferase reporter assays, western blots and immunofluorescence assays in vitro, with echocardiography, qRT‐PCR and immunohistochemical methods in vivo.Key ResultsXMU‐MP‐1 treatment significantly increased activity of the Hippo pathway effector yes‐associated protein and inhibited phenylephrine‐induced hypertrophy in NRCM. XMU‐MP‐1 improved cardiomyocyte survival and reduced apoptosis following oxidative stress. In vivo, mice 3 weeks after TAC, were treated with XMU‐MP‐1 (1 mg·kg−1) every alternate day for 10 further days. XMU‐MP‐1‐treated mice showed better cardiac contractility than vehicle‐treated mice. Cardiomyocyte cross‐sectional size and expression of the hypertrophic marker, brain natriuretic peptide, were reduced in XMU‐MP‐1‐treated mice. Improved heart function in XMU‐MP‐1‐treated mice with TAC, was accompanied by fewer TUNEL positive cardiomyocytes and lower levels of fibrosis, suggesting inhibition of cardiomyocyte apoptosis and decreased fibrosis.Conclusions and ImplicationsThe Hippo pathway inhibitor, XMU‐MP‐1, reduced cellular hypertrophy and improved survival in cultured cardiomyocytes and, in vivo, preserved cardiac function following pressure overload.

show abstract

Multifunctional Nanohybrid Based on Porous Silicon Nanoparticles, Gold Nanoparticles, and Acetalated Dextran for Liver Regeneration and Acute Liver Failure Theranostics

Cited by 90 publications

References 44 publications

Microfluidics for Production of Particles: Mechanism, Methodology, and Applications

Microfluidics for Production of Particles: Mechanism, Methodology, and Applications

Dextran‐based hydrogel with enhanced mechanical performance via covalent and non‐covalent cross‐linking units carrying adipose‐derived stem cells toward vascularized bone tissue engineering

Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU‐MP‐1, protects the heart against adverse effects during pressure overload

Contact Info

Product

Resources

About